In our study, we reveal a possible inhibitory immune checkpoint molecule TNFRSF9 for breast cancer treatment where the agonistic antibody of TNFRSF9 may be effective for breast cancer immunotherapy. Here, TNFRSF9 is linked to breast carcinoma.